Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ).
JW (Cayman) Therapeutics Co. Ltd held an Extraordinary General Meeting (EGM) on June 3, 2025, where an ordinary resolution regarding the approval, ratification, and confirmation of a License Agreement was passed unanimously. The resolution’s approval, with 100% of the votes in favor, signifies a strategic move for the company, potentially enhancing its operational capabilities and market position in the biotechnology sector.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of cell-based immunotherapies for cancer treatment.
Average Trading Volume: 1,682,541
Technical Sentiment Signal: Buy
Current Market Cap: HK$815.7M
See more data about 2126 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue